Next Article in Journal
Acknowledgement to Reviewers of Vaccines in 2018
Previous Article in Journal
Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays?
Article Menu

Export Article

Reply published on 15 March 2019, see Vaccines 2019, 7(1), 32.

Open AccessArticle
Vaccines 2019, 7(1), 5; https://doi.org/10.3390/vaccines7010005

Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhea in New Zealand: A Retrospective Cohort Study

1
Department of General Practice and Primary Health, University of Auckland, Auckland 1142, New Zealand
2
Sexual Health Services Waikato District Health Board and Honorary Senior Lecturer, School of Medicine, University of Auckland, Auckland 1142, New Zealand
3
Department of Social and Community Health, University of Auckland, Auckland 1142, New Zealand
4
Department of Pediatrics, Cincinnati Children’s Hospital, Cincinnati, OH 45229-3039, USA
5
Immunisation Advisory Centre, Department of General Practice and Primary Health Care, University of Auckland, Auckland 1142, New Zealand
*
Author to whom correspondence should be addressed.
Received: 28 June 2018 / Revised: 19 December 2018 / Accepted: 24 December 2018 / Published: 5 January 2019
Full-Text   |   PDF [218 KB, uploaded 5 January 2019]

Abstract

Gonorrhea is a major global public health problem with emergence of multiple drug-resistant strains with no effective vaccine. This retrospective cohort study aimed to estimate the effectiveness of the New Zealand meningococcal B vaccine against gonorrhea-associated hospitalization. The cohort consisted of individuals born from 1984 to 1999 residing in New Zealand. Therefore, it was eligible for meningococcal B vaccination from 2004 to 2008. Administrative datasets of demographics, customs, hospitalization, education, income tax, and immunization were linked using the national Integrated Data Infrastructure. The primary outcome was hospitalization with a primary diagnosis of gonorrhea. Cox’s proportional hazards models were applied with a Firth correction for rare outcomes to generate estimates of hazard ratios. Vaccine effectiveness estimates were calculated as 1-Hazard Ratio expressed as a percentage. There were 1,143,897 eligible cohort members with 135 missing information on gender, 16,245 missing ethnicity, and 197,502 missing deprivation. Therefore, only 935,496 cohort members were included in the analysis. After adjustment for gender, ethnicity, and deprivation, vaccine effectiveness (MeNZB™) against hospitalization caused by gonorrhea was estimated to be 24% (95% CI 1–42%). In conclusion, the data suggests vaccination with MeNZB™ significantly reduced the rate of hospitalization from gonorrhea. This supports prior research indicating possible cross protection of this vaccine against gonorrhea acquisition and disease in the outpatient setting. View Full-Text
Keywords: gonorrhea; outer membrane vesicle vaccine; group B meningococcus; cohort study; New Zealand gonorrhea; outer membrane vesicle vaccine; group B meningococcus; cohort study; New Zealand
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Paynter, J.; Goodyear-Smith, F.; Morgan, J.; Saxton, P.; Black, S.; Petousis-Harris, H. Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhea in New Zealand: A Retrospective Cohort Study. Vaccines 2019, 7, 5.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top